Frontiers in Oncology (Nov 2021)
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
- Weiping Liu,
- Donglu Zhao,
- Ting Liu,
- Ting Niu,
- Yongping Song,
- Wei Xu,
- Jie Jin,
- Qingqing Cai,
- Huiqiang Huang,
- Zhiming Li,
- Ming Hou,
- Huilai Zhang,
- Jianfeng Zhou,
- Jianda Hu,
- Jianzhen Shen,
- Yuankai Shi,
- Yu Yang,
- Liling Zhang,
- Weili Zhao,
- Kaiyang Ding,
- Lugui Qiu,
- Huo Tan,
- Zhihui Zhang,
- Lihong Liu,
- Jinghua Wang,
- Bing Xu,
- Hui Zhou,
- Guangxun Gao,
- Hongwei Xue,
- Ou Bai,
- Ru Feng,
- Xiaobing Huang,
- Haiyan Yang,
- Xiaojing Yan,
- Qingshu Zeng,
- Peng Liu,
- Wenyu Li,
- Min Mao,
- Hang Su,
- Xin Wang,
- Jingyan Xu,
- Daobin Zhou,
- Hongyu Zhang,
- Jun Ma,
- Zhixiang Shen,
- Jun Zhu
Affiliations
- Weiping Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China
- Donglu Zhao
- Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin, China
- Ting Liu
- Department of Hematology, West China Hospital Sichuan University, Chengdu, China
- Ting Niu
- Department of Hematology, West China Hospital Sichuan University, Chengdu, China
- Yongping Song
- Department of Hematology, Henan Cancer Hospital, Zhengzhou, China
- Wei Xu
- Department of Hematology, Jiangsu Province Hospital, Nanjing, China
- Jie Jin
- Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China
- Qingqing Cai
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Huiqiang Huang
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Zhiming Li
- Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- Ming Hou
- Department of Hematology, Qilu Hospital Shandong University, Jinan, China
- Huilai Zhang
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- Jianfeng Zhou
- 0Department of Hematology, Tongji Hospital Huazhong University of Science and Technology, Wuhan, China
- Jianda Hu
- 1Department of Hematology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, China
- Jianzhen Shen
- 1Department of Hematology, The Affiliated Union Hospital of Fujian Medical University, Fuzhou, China
- Yuankai Shi
- 2Department of Medical Oncology, The Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, China
- Yu Yang
- 3Department of Lymphoma, Fujian Cancer Hospital, Fuzhou, China
- Liling Zhang
- 4Department of Medical Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
- Weili Zhao
- 5Department of Hematology, Shanghai Rui Jin Hospital, Shanghai, China
- Kaiyang Ding
- 6Department of Hematology, Anhui Provincial Cancer Hospital, Hefei, China
- Lugui Qiu
- 7Department of Hematology, The Hematology Institute and Hospital Chinese Academy of Medical Sciences, Tianjin, China
- Huo Tan
- 8Department of Hematology, The First Affiliated Hospital Guangzhou Medical University, Guangzhou, China
- Zhihui Zhang
- 9Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China
- Lihong Liu
- 0Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
- Jinghua Wang
- 1Department of Medical Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, China
- Bing Xu
- 2Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, China
- Hui Zhou
- 3Department of Lymphoma, Hunan Cancer Hospital, Changsha, China
- Guangxun Gao
- 4Department of Hematology, Xijing Hospital of Airforce Medical University, Xi’an, China
- Hongwei Xue
- 5Department of Lymphoma, The Affiliated Hospital of Qingdao University, Qingdao, China
- Ou Bai
- 6Department of Hematology, The First Bethune Hospital of Jilin University, Changchun, China
- Ru Feng
- 7Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China
- Xiaobing Huang
- 8Department of Hematology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China
- Haiyan Yang
- 9Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou, China
- Xiaojing Yan
- 0Department of Hematology, The First Hospital of China Medical University, Shenyang, China
- Qingshu Zeng
- 1Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China
- Peng Liu
- 2Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China
- Wenyu Li
- 3Department of Lymphoma, Guangdong Provincial People’s Hospital, Guangzhou, China
- Min Mao
- 4Department of Hematology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumchi, China
- Hang Su
- 5Department of Lymphoma, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China
- Xin Wang
- 6Department of Hematology, Shandong First Medical University Affiliated Provincial Hospital, Jinan, China
- Jingyan Xu
- 7Department of Hematology, Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
- Daobin Zhou
- 8Department of Hematology, Peking Union Medical College Hospital, Beijing, China
- Hongyu Zhang
- 9Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China
- Jun Ma
- Department of Hematology and Oncology, Harbin Institute of Hematology and Oncology, Harbin, China
- Zhixiang Shen
- 5Department of Hematology, Shanghai Rui Jin Hospital, Shanghai, China
- Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China
- DOI
- https://doi.org/10.3389/fonc.2021.750323
- Journal volume & issue
-
Vol. 11
Abstract
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1–2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy.
Keywords
